Chongqing Pharscin Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Chongqing Pharscin Pharmaceutical's earnings have been declining at an average annual rate of -14.4%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 0.9% per year. Chongqing Pharscin Pharmaceutical's return on equity is 4.3%, and it has net margins of 9.5%.
Key information
-14.4%
Earnings growth rate
-14.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 0.9% |
| Return on equity | 4.3% |
| Net Margin | 9.5% |
| Next Earnings Update | 29 Apr 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Chongqing Pharscin Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 739 | 70 | 283 | 69 |
| 30 Jun 23 | 778 | 88 | 301 | 67 |
| 31 Mar 23 | 770 | 99 | 294 | 64 |
| 31 Dec 22 | 785 | 98 | 296 | 59 |
| 30 Sep 22 | 762 | 75 | 293 | 55 |
| 30 Jun 22 | 778 | 87 | 287 | 46 |
| 31 Mar 22 | 819 | 85 | 297 | 44 |
| 01 Jan 22 | 846 | 92 | 297 | 42 |
| 30 Sep 21 | 903 | 114 | 284 | 39 |
| 30 Jun 21 | 939 | 113 | 282 | 40 |
| 31 Mar 21 | 942 | 128 | 273 | 38 |
| 31 Dec 20 | 882 | 119 | 268 | 36 |
| 30 Sep 20 | 840 | 127 | 282 | 33 |
| 30 Jun 20 | 816 | 140 | 297 | 30 |
| 31 Mar 20 | 821 | 166 | 315 | 24 |
| 31 Dec 19 | 842 | 170 | 334 | 26 |
| 30 Sep 19 | 796 | 163 | 331 | 22 |
| 30 Jun 19 | 756 | 167 | 327 | 18 |
| 31 Mar 19 | 730 | 139 | 323 | 20 |
| 31 Dec 18 | 703 | 137 | 316 | 15 |
| 30 Sep 18 | 686 | 131 | 309 | 13 |
| 30 Jun 18 | 661 | 128 | 293 | 15 |
| 31 Mar 18 | 631 | 120 | 288 | 10 |
| 31 Dec 17 | 592 | 112 | 270 | 9 |
| 30 Sep 17 | 602 | 112 | 268 | 4 |
| 31 Dec 16 | 552 | 96 | 249 | 0 |
| 31 Dec 15 | 469 | 74 | 205 | 0 |
| 31 Dec 14 | 426 | 59 | 203 | 0 |
Quality Earnings: 002907 has a large one-off gain of CN¥18.4M impacting its last 12 months of financial results to 30th September, 2023.
Growing Profit Margin: 002907's current net profit margins (9.5%) are lower than last year (9.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002907's earnings have declined by 14.4% per year over the past 5 years.
Accelerating Growth: 002907's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002907 had negative earnings growth (-6.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.5%).
Return on Equity
High ROE: 002907's Return on Equity (4.3%) is considered low.